05.01.2017
MorphoSys AG DE0006632003
DGAP-News: Dr. Malte Peters to become new Chief Development Officer of MorphoSys AG
DGAP-News: MorphoSys AG / Key word(s): Change of Personnel
Dr. Malte Peters to become new Chief Development Officer of MorphoSys AG
05.01.2017 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, January 5, 2017
Dr. Malte Peters to become new Chief Development Officer of MorphoSys AG
The Supervisory Board of MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime
Standard Segment, TecDAX; OTC: MPSYY) has appointed Dr. Malte Peters as
Chief Development Officer. Dr. Peters will take up the position on March 1,
2017 and will succeed Dr. Arndt Schottelius, who is leaving to pursue other
opportunities. Dr. Peters joins MorphoSys from Sandoz, where he serves as
Global Head, Clinical Development Biopharmaceuticals.
Dr. Peters built his career in early and late-stage clinical development
over the last 18 years. Prior to his latest role at Sandoz, he spent 12
years in various managerial positions within Novartis focusing on
management of clinical development projects in oncology. Before that, Dr.
Peters served in positions as Medical Director at Micromet AG and as Head
of Translational Research and Pharmacogenomics at Merck KGaA.
"Dr. Peters is an ideal addition to the Management Board of MorphoSys at
this stage of the Company's growth. Drawing on his deep operational and
medical experience in oncology and immunology, he will focus his efforts on
the development of our clinical and pre-clinical programs, the most
valuable assets driving our future growth. We look forward to welcoming him
to MorphoSys." commented Dr. Gerald Möller, Chairman of the Supervisory
Board of MorphoSys AG. "We would like to thank Dr. Schottelius for his
invaluable contribution over the past eight years. He has built up the
development area and was instrumental in transforming MorphoSys into a
credible development organization with a very promising product portfolio.
We wish him the very best for the future."
Dr. Malte Peters' picture and CV can be downloaded here:
www.morphosys.de/download
About MorphoSys
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic pipeline of more than 100 human antibody drug candidates for
the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to
name just a few. With its ongoing commitment to new antibody technology and
drug development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit http://
www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R),
Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the
MorphoSys Group.
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-
looking statements as far as the wording of the relevant press release is
concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
05.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
534257 05.01.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR